When statin-sensitive MM tumors are identified, atorvastatin can be used safely and effectively to decrease tumor burden. Sublethally irradiated NOD/SCID mice were intravenously injected with KMS11-luc cells. The animals received 10 or 50 mg/kg atorvastatin or a PBS vehicle control by oral gavage 3 times a week for 37 days, until the tumor bioluminescence in the control mice saturated the detectors. When subsequently injected with luciferin, the bioluminescent myeloma cells in these animals were imaged (A; Day 31) and quantified over several weeks (B). *P < .001 (1-way analysis of variance comparing each atorvastatin group with the PBS group). (C) Survival curves were determined based on when the mice were humanely killed after the onset of hind-limb paralysis resulting from tumor burden. Arrows indicate the beginning (day 2) and endpoints (day 37) of treatment. Each group composed of 7 or 8 mice. Data are mean ± SD.